Protein degradation–focused Lycia Therapeutics launches with $50 million from Versant
Friday, June 12, 2020 - 13:30
in Biology & Nature
Using technology from chemical biologist Carolyn Bertozzi's lab, the firm wants to develop drugs that can break down extracellular proteins